The standardization of immunotherapy as a treatment for patients without known molecular targets, based on the immunohistochemical expression of PD-L1 [17,18] in tumor cells, has significantly contributed to this field, not only in adenocarcinoma but also in other NSCLC subtypes. This evidence concerns the gene CD274 and non-small cell lung carcinoma.